Healthcare, Pharma & Life Sciences

Novartis Pays Abogen $575M Upfront for mRNA T-Cell Engager Rights

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.

Novartis secures exclusive worldwide license to Abogen's lead autoimmune asset ABO2203

The licensing and option agreement grants Novartis an exclusive global license to ABO2203, which Abogen describes as the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. The molecule uses mRNA to direct endogenous production of T-cell engagers in vivo, targeting B-cell depletion through a mechanism the companies say differs from traditional recombinant T-cell engagers.

Hansoh's Olatorepatide Shows 19.3% Weight Loss at Week 48 in Phase III Trial

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.

The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.

Trial enrolled 604 participants across four dose arms over 48 weeks

Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.

MontoHealth Builds AI Action Layer to Automate Patient Workflows

Image
MontoHealth Builds AI Action Layer to Automate Patient Workflows

San Francisco -- October 02, 2026 -- MontoHealth is developing an AI-driven action layer designed to execute routine healthcare tasks—not just discuss them—across existing hospital and clinic software systems.

MontoHealth targets the gap between digitized records and automated work

Despite two decades of healthcare digitization, tasks such as rescheduling an appointment, routing a prescription refill, coordinating a referral or resolving an insurance query still require manual phone calls and handoffs across disconnected systems. Healthcare organizations typically operate EHRs, scheduling platforms, billing systems and patient portals as separate applications, each governed by distinct privacy and security controls. MontoHealth argues that digitizing a workflow has not equated to automating it, leaving staff to perform the connective work between systems.

Angelalign Launches Pressure Points to Replace Torque Ridges in Europe

Image
Angelalign Launches Pressure Points to Replace Torque Ridges in Europe

San Clemente, Calif. – October 02, 2026 -- Angelalign Technology Inc. (6699.HK) has launched Pressure Points in the European market, a feature that replaces its existing Torque Ridges and delivers a 25% increase in tooth surface contact in its single pressure point configuration.

Angelalign replaces hand-made dimples with a digitally scalable force-control feature

Pressure Points is engineered to apply force at or near the center of the contact point, a departure from the hand-made dimples orthodontists have long used to correct torque and rotation. The company states the simplified dimple shape improves predictability of force application compared with current methods.

GMP Labeling Flags Supply Chain Risk in Pharma Compliance Labels

Image
GMP Labeling Flags Supply Chain Risk in Pharma Compliance Labels

Granite Bay, Calif. – October 02, 2026 -- GMP Labeling Inc. is marking Manufacturing Day 2026 by positioning its nearly 40-year domestic production history as a hedge against global supply chain disruption for pharmaceutical and biotechnology manufacturers. The California-based company, founded in 1987, manufactures quality control labels, sample identification tags, and equipment status markers used across regulated production lines.

Label failures can halt regulated production lines

Material inconsistencies or shipping delays in compliance labeling can interrupt manufacturing workflows, complicate federal audits, and compromise quality records, according to the company. Robin Kalsbeek, General Manager of GMP Labeling, said a label functions as a critical element of traceability and compliance rather than a minor supply item in biotechnology and medical manufacturing settings.

Curaleaf's QMID Becomes First TGA-Registered Cannabis Inhaler in Australia

Image
Curaleaf's QMID Becomes First TGA-Registered Cannabis Inhaler in Australia

London – October 02, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.

TGA Grants Class IIb Status to QMID on October 02, 2026

The device, developed with Jupiter Research LLC, was listed in the Australian Register of Therapeutic Goods as a Class IIb Medical Device, marking the first regulatory approval in Australia for a device delivering Cannabis Sativa L. extracts via patient inhalation. The approval follows a multi-year regulatory process and arrives one year after QMID received EU Medical Device Registration.

SAS, NC State Launch AI Research Partnership for Drug Discovery

Image
SAS, NC State Launch AI Research Partnership for Drug Discovery

Cary, N.C. – October 02, 2026 -- SAS and North Carolina State University have launched the SAS Think & Do Tank, a two-year pilot research partnership applying data and AI to human health, nutrition and environmental resilience challenges, 50 years after SAS originated from an NC State agricultural research project.

Partnership targets faster drug discovery through translational predictive biology

One of the initiative's first research efforts focuses on translational predictive biology, combining studies in living systems with advanced lab models such as organoids and organ-on-chip technologies that mimic human organ function. NC State researchers aim to build predictive models that help identify promising treatments earlier, explain why interventions succeed or fail, and cut the time and cost of moving new therapies toward clinical use.

Banner Capital Forms Seaway Group to Buy Three Medical Device Manufacturers

Image
Banner Capital Forms Seaway Group to Buy Three Medical Device Manufacturers

Salt Lake City – October 02, 2026 -- Banner Capital has formed Seaway Group and signed a definitive agreement to acquire three medical device manufacturing businesses -- Seaway Plastics Engineering, MME Group and Wright Engineered Plastics -- in a transaction expected to close in the fourth quarter of 2026, subject to customary closing conditions.

Seaway Group becomes the third platform in Banner Capital Fund II

The deal follows Banner Capital's prior platform launches of Western Pavement Services and Roof Restoration Group, extending the Salt Lake City-based private equity firm's push into essential, founder-led businesses beyond its traditional commercial-services focus.

Encompass Health to Report Q3 2026 Results Oct. 28

Image
Encompass Health to Report Q3 2026 Results Oct. 28

Birmingham, Ala. – October 02, 2026 -- Encompass Health Corp. (NYSE: EHC) will release third-quarter 2026 financial results after market close on Wednesday, Oct. 28, 2026.

Company schedules investor call for Oct. 29 at 10 a.m. ET

Encompass Health will host a conference call the following morning to discuss the quarterly results with investors. Domestic participants can dial 833-354-6854 using conference ID EHCQ326, while international callers should use 785-838-9343 with the same ID.

Live webcast and replay available on investor site

A live webcast of the call, along with an online replay, will be accessible through the company's investor relations website. Encompass Health operates 177 inpatient rehabilitation hospitals across 39 states and Puerto Rico, making it the largest owner and operator of such facilities in the United States.

Genomma Lab to Report Q3 2026 Earnings Oct. 21, Call Oct. 22

Mexico City – October 02, 2026 -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) will release its Third Quarter 2026 earnings results on Wednesday, October 02, 2026, after the close of the Mexican Stock Exchange.

Executive team to brief investors on October 22 call

The company will hold a conference call on Thursday, October 02, 2026, at 11:00 a.m. Mexico City Time to discuss the quarterly financial results. Chief Executive Officer Marco Sparvieri, Chief Financial Officer Antonio Zamora, and Investor Relations Officer Christianne Ibanez will present on the call.

Webcast registration required for access

Investors seeking to join the call must register via a direct webcast link, after which they will receive an email confirmation with an invitation. Genomma Lab shares trade on the Mexican Stock Exchange under the ticker LAB B, with the Bloomberg code LABB:MM.